List of Excipients in Branded Drug DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Atlantic Biologicals Corps	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	diphenoxylate hydrochloride and atropine sulfate	17856-1061	ACACIA
Atlantic Biologicals Corps	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	diphenoxylate hydrochloride and atropine sulfate	17856-1061	MAGNESIUM STEARATE
Atlantic Biologicals Corps	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	diphenoxylate hydrochloride and atropine sulfate	17856-1061	SORBITOL
Atlantic Biologicals Corps	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	diphenoxylate hydrochloride and atropine sulfate	17856-1061	STARCH, CORN

Generic Drugs Containing DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	diphenoxylate hydrochloride and atropine sulfate	0054-3194	ALCOHOL
Hikma Pharmaceuticals USA Inc	diphenoxylate hydrochloride and atropine sulfate	0054-3194	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	diphenoxylate hydrochloride and atropine sulfate	0054-3194	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	diphenoxylate hydrochloride and atropine sulfate	0054-3194	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE?

# Of NDCs	Excipient
3	ACACIA
3	ALCOHOL
3	ANHYDROUS CITRIC ACID
3	CALCIUM STEARATE

Excipient Strategy and Commercial Opportunities for Diphenoxylate Hydrochloride and Atropine Sulfate

Last updated: February 27, 2026

What are the key excipient considerations for Diphenoxylate Hydrochloride and Atropine Sulfate formulations?

Diphenoxylate Hydrochloride and Atropine Sulfate are combined as an antidiarrheal therapy. The formulation requires excipients compatible with both active ingredients to ensure stability, bioavailability, and patient safety. Common excipients include binders, fillers, disintegrants, lubricants, preservatives, and pH adjusters.

Core excipient functions:

• Binders: Microcrystalline cellulose ensures tablet integrity.
• Fillers: Lactose or dibasic calcium phosphate facilitate manufacturing.
• Disintegrants: Cross-linked starches promote tablet breakup.
• Lubricants: Magnesium stearate aids tablet compression.
• Preservatives: Benzalkonium chloride maintains sterility in liquid formulations.
• pH Adjusters: Citric acid or sodium hydroxide optimize solubility and stability.

How does excipient selection influence formulation stability?

Diphenoxylate Hydrochloride and atropine sulfate are sensitive to moisture, light, and pH variations. Excipients such as film-coatings with antioxidants (e.g., tocopherols) can minimize oxidative degradation. The choice of anhydrous excipients reduces hydrolytic instability. Compatibility testing is essential to prevent interactions that could compromise drug potency or cause discoloration or decomposition.

What are potential barriers and opportunities in excipient innovation?

Barriers:

• Regulatory constraints limit use of certain excipients (e.g., benzalkonium chloride in parenteral forms).
• Compatibility issues between excipients and both active ingredients require extensive testing.
• Variability in excipient quality can impact batch consistency.

Opportunities:

• Development of sustained-release excipients can enhance dosing compliance.
• Use of novel disintegrants or binders may improve bioavailability.
• Incorporation of excipients with bitterness masking properties can improve patient acceptance.

What are the commercial implications of excipient strategies?

Effective excipient selection can extend shelf life, reduce manufacturing costs, and improve therapeutic stability. Innovating with excipients offers differentiation in generic and branded formulations, catering to market preferences for lower excipient allergenicity. Patent protection may be achievable through formulations leveraging novel excipients or delivery mechanisms.

Market overview: Diphenoxylate Hydrochloride and Atropine Sulfate

• Market size: Estimated USD 800 million globally in 2022, with growth driven by approvals in emerging markets.
• Key players: Janssen, Teva, Mylan, Sun Pharma.
• Formulation types: Tablets (most common), liquids, injectables.
• Patents: Several patents expired, paving the way for generic entrants; innovation in formulation remains critical for differentiation.

Regulatory considerations

• FDA: Monographs specify excipient limits; deviations require approval.
• EMA: Emphasizes excipient purity and documented compatibility.
• ICH Guidelines: Encourage stability testing with chosen excipients under ICH Q1 conditions.

Strategic recommendations

• Focus on excipient compatibility to develop stable, high-bioavailability formulations.
• Explore excipient innovations such as controlled-release matrices.
• Leverage patents on novel excipient combinations to secure competitive advantage.
• Invest in formulations that reduce excipient-related allergies and sensitivities.

Key takeaways

• Excipient strategy must consider chemical compatibility, stability, and delivery goals.
• Innovation in excipients can unlock new commercial opportunities, including extended patent exclusivity.
• Regulatory compliance influences excipient choices, requiring thorough compatibility testing.
• The existing market size and patent expirations create opportunities for generic and biosimilar development, provided excipient strategies optimize formulation stability and patient compliance.

FAQs

1. Which excipients are most common in Diphenoxylate Hydrochloride and Atropine Sulfate formulations?
Microcrystalline cellulose, lactose, cross-linked starches, magnesium stearate, and citric acid are common. Their selection depends on the formulation type.

2. How can excipient choice affect formulation stability?
Excipients impact moisture sensitivity, oxidation, pH stability, and compatibility, which influence shelf life and efficacy.

3. What innovations are possible in excipient development for this drug?
Sustained-release matrices, taste-masking agents, and novel disintegrants can improve dosing, patient acceptance, and bioavailability.

4. How does excipient variability influence market competitiveness?
Consistent quality ensures regulatory compliance and batch-to-batch uniformity, impacting safety and efficacy.

5. Can proprietary excipients extend patent protection?
Yes. Patents on specialized excipients or delivery mechanisms provide differentiation advantages in competitive markets.

---

References

[1] United States Food and Drug Administration (FDA). (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency (EMA). (2021). Guidelines on excipients.
[3] International Council for Harmonisation (ICH). (2003). ICH Q1 Stability Guidelines.